Table 2.
Frequency and changes in frequency of bowel movements
| Variable | Placebo | Prucalopride 2 mg | Prucalopride 4 mg |
|---|---|---|---|
| Mean (SE) average weekly frequency of SCBMa | |||
| Baseline | 0.3 (0.07) | 0.5 (0.11) | 0.3 (0.08) |
| Week 1 | 0.6 (0.14) | 1.6 (0.28) | 1.8 (0.35)** |
| Weeks 1–4 | 0.9 (0.17) | 1.6 (0.25) | 1.4 (0.23) |
| Mean (SE) average weekly frequency of SBMb | |||
| Baseline | 1.5 (0.23) | 2.3 (0.23) | 2.4 (0.36) |
| Week 1 | 2.9 (0.34) | 4.5 (0.40) | 6.0 (0.62)*** |
| Weeks 1–4 | 3.0 (0.34) | 4.5 (0.42) | 4.9 (0.60)* |
| Proportion of patients with an average increase of ≥1 BM per week, n (%)c | |||
| Week 1 | 22 (34.4) | 28 (43.8) | 37 (61.7)** |
| Weeks 1–4 | 15 (25.0) | 22 (36.1) | 24 (41.4) |
| Proportion of patients with an average increase of ≥1 SBM per week, n (%)d | |||
| Week 1 | 28 (43.8) | 37 (57.8) | 45 (75.0)*** |
| Weeks 1–4 | 29 (48.3) | 33 (54.1) | 37 (63.8) |
a,b* P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, pairwise comparison of change from baseline versus placebo
c,d** P ≤ 0.01, *** P < 0.001, pairwise comparison versus placebo